Genor Biopharma Holdings (HKSE:06998) Margin of Safety % (DCF FCF Based) : N/A (As of Apr. 12, 2025)

View and export this data going back to 2020. Start your Free Trial

What is Genor Biopharma Holdings Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Genor Biopharma Holdings's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

Competitive Comparison of Genor Biopharma Holdings's Margin of Safety % (DCF FCF Based)

For the Biotechnology subindustry, Genor Biopharma Holdings's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genor Biopharma Holdings's Margin of Safety % (DCF FCF Based) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genor Biopharma Holdings's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Genor Biopharma Holdings's Margin of Safety % (DCF FCF Based) falls into.

Save Embed

;

Save Embed

;

Genor Biopharma Holdings Margin of Safety % (DCF FCF Based) Related Terms

Thank you for viewing the detailed overview of Genor Biopharma Holdings's Margin of Safety % (DCF FCF Based) provided by GuruFocus.com. Please click on the following links to see related term pages.

Genor Biopharma Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genor Biopharma Holdings Ltd (HKSE:06998) » Definitions » Margin of Safety % (DCF FCF Based)

Comparable Companies

Traded in Other Exchanges

67N:Germany

Address

690 Bibo Road, Room 401-17, Building 6, Pudong New District, Shanghai, CHN, 201203

Website

https://www.genorbio.com

Genor Biopharma Holdings Ltd is a commercial-ready biopharmaceutical company focusing on developing and commercializing oncology and autoimmune drugs. The company is focused on therapeutic areas with substantial unmet medical needs in oncology, autoimmune, and other chronic diseases. Its key drug candidates include GB491 (lerociclib), a differentiated oral CDK4/6 inhibitor; GB221, a novel HER2 mAb drug candidate; geptanolimab (GB226), GB492, a STING agonist expected to exert synergistic effects in combination with GB226; GB242, an infliximab (Remicade) biosimilar; and GB223, a RANKL, and others.

Executives

Forebright New Opportunities Fund, L.p.	2101 Beneficial owner
Forbright Global Limited	2201 Interest of corporation controlled by you
Fnof Gp Limited	2201 Interest of corporation controlled by you
Deg – Deutsche Investitions- Und Entwicklungsgesellschaft Mbh	2101 Beneficial owner
Hsg Growth V Holdco Q, Ltd.	2101 Beneficial owner
Hsg Holding Limited	2201 Interest of corporation controlled by you
Snp China Enterprises Limited	2201 Interest of corporation controlled by you
Hongshan Capital Growth Fund Management I, L.p.	2201 Interest of corporation controlled by you
Shen Nan Peng	2201 Interest of corporation controlled by you
Hongshan Capital Growth Fund I, L.p.	2101 Beneficial owner
Hongshan Capital Growth Fund V, L.p.	2201 Interest of corporation controlled by you
Hsg Growth V Management, L.p.	2201 Interest of corporation controlled by you
Hongshan Capital Management I, L.p.	2201 Interest of corporation controlled by you
Hongshan Capital I, L.p.	2101 Beneficial owner
Ni Xin	2101 Beneficial owner

Genor Biopharma Holdings Headlines

No Headlines